Generic name: brolucizumab
Disease: wet age-related macular degeneration
2024 sales estimate: $1.38 billion
Regeneron and Roche are already duking it out in wet age-related macular degeneration with Eylea and Lucentis, and they may have more company later this year.
In April, Novartis’ brolucizumab scored an FDA priority review, setting the drug up for a possible U.S. nod in October. Novartis laid out a priority review voucher to win the quick review, showing just how enthusiastic the company is about the prospective launch.
As further evidence that Novartis is intent on the impending showdown, it's been staffing up in key regions ahead of the FDA decision, an executive told FiercePharma earlier this year. The company submitted two phase 3 trials called Hawk and Harrier to support its FDA application.
EvaluatePharma has predicted the drug will generate $1.38 billion by 2024.
But Roche and Regeneron aren’t just sitting around waiting for the Novartis’ nod. Roche has its own next-generation AMD contender in faricimab, a phase 3 prospect. For its part, Regeneron recently scored a diabetic retinopathy approval for Eylea.